PCRX Company Profile and Key Details

PCRX has shown weak momentum, losing -15.83% over the past week and -15.61% over the past quarter, though year-to-date performance is down -25.43%. Short-term trend indicators are bullishly aligned (SMA20 3.41%, SMA50 -1.74%, SMA200 -5.58%). The stock’s 14-day RSI is 52.66 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -18.27% below its high and over 20.16% above its low. Average 10-day trading volume of 513.81 thousand shares is in line with the 3-month average of 492.34 thousand, indicating normal recent market interest.

Pacira BioSciences, Inc. has 44.93 million shares outstanding. The public float is 39.83 million shares, elevated short interest at 20.07% of float. This equals 6.29 million shares. The short ratio is 8.14 days. Institutional investors hold 117.5% of the float. Insiders own 1.77%. SLONIN JONATHAN holds 223.64 thousand shares, WILLIAMS KRISTEN has 167.06 thousand shares and STACK DAVID M has 153.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 60.84 thousand shares across 10 transactions.

Pacira BioSciences, Inc. generated EPS of $0.45 over the past year. Five-year average earnings growth is -51.99%. Wall Street analysts project EPS growth of 6.33% annually over the next five years. The latest quarter delivered EPS of $0.07. The next quarter is forecast at $0.90. Next year's EPS is expected at $23.01. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $24.00. The high target offers 55.93% upside. The low target suggests -1.52% downside. The mean target is $30.25. This offers 24.13% upside. Pacira BioSciences, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -87.23%. The prior quarter beat by -32.94%. Over the last six quarters, Apple has recorded several small beats. These include 16.67% in February 27, 2025.

Pacira BioSciences, Inc. (NASDAQ:PCRX) closed at $24.37 USD, gaining $0.41 (1.71%) from the previous close of $23.96. The stock is currently mid-range between its 52-week high and low $18.80 and $27.64. With a market capitalization of about $958.59 million, Pacira BioSciences, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 523.86 thousand shares, volume is running light vs its 52-week average. Headquartered in Tampa, FL, Pacira BioSciences, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Frank D. Lee, the company employs approximately 788 people and listed since February 03, 2011. Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health.

Pacira BioSciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $58.35. This means the shares are trading below this model’s fair value.

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares are down -25.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pacira BioSciences, Inc. trading at a premium to the broader market with a P/E of 197.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $49.31, suggesting 102.34% upside. Our AI forecast model points to short-term weakness (-3.57% over two weeks), a medium-term fall (-14.24% over three months), and a longer-term loss (-27.29% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pacira BioSciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.57%, with price expected at $23.50 by July 08, 2026, within a range of $22.86 to $24.18 3-Month Outlook: Projected fall of -14.24%, reaching $20.90 by September 22, 2026, with a range of $18.35 to $22.76. 1-Year Outlook: Projected loss of -27.29%, with price at $17.72 by June 24, 2027, within a range of $15.63 to $19.90.

Pacira BioSciences, Inc. trades at a P/E ratio of 197.55, slightly above the S&P 500 average, with a price-to-sales ratio of 1.29 and a price-to-book ratio of 1.49 suggesting the stock is closer to book value. The P/FCF stands at 7.15, also above market averages.